OnCo
trialsTrialPositive

EV-302 / KEYNOTE-A39

Nearly doubled survival in advanced bladder cancer, ending 40 years of platinum chemotherapy as the standard.

OS 31.5 vs 16.1 months (HR 0.47); PFS HR 0.45. The template for ADC + checkpoint inhibitor combinations now being copied in breast (ASCENT-04) and lung cancer.

Setting
First-line advanced urothelial cancer: enfortumab vedotin + pembrolizumab vs platinum chemotherapy
Phase
Phase 3
Sponsor
Astellas / Pfizer / Merck
Registry
Headline result
OS HR 0.47.
Reported
2023
Enrolled
886
Replication
Confirms EV-103 (phase 1b/2, ORR 68%); the extended follow-up in 2025 maintained the OS hazard ratio.

Outcomes

3top
In plain words
What these results mean for people, not percentages
886 people took part
Progression-free survival (BICR)primarysurrogate endpoint
  • Median 12.5 vs 6.3 months with Enfortumab vedotin + pembrolizumab compared with Platinum + gemcitabine; about 6.2 months longer for half the group.
  • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
  • Put another way, the treated group had about 55 percent lower chance of the event at any given time (hazard ratio 0.45, likely range 0.38 to 0.54).
  • This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
Overall survivalprimarysurvival endpoint
  • Median 31.5 vs 16.1 months with Enfortumab vedotin + pembrolizumab compared with Platinum + gemcitabine; about 15.4 months longer for half the group.
  • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
  • Put another way, the treated group had about 53 percent lower chance of the event at any given time (hazard ratio 0.47, likely range 0.38 to 0.58).
  • Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
Objective response rateresponse endpoint
  • 67.7 vs 44.4 out of 100 had their tumour shrink with Enfortumab vedotin + pembrolizumab compared with Platinum + gemcitabine; 23.3 more per 100.
  • Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
  • A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
Be careful
  • These results apply to the people the trial enrolled: First-line advanced urothelial cancer: enfortumab vedotin + pembrolizumab vs platinum chemotherapy. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

886 participants enrolled.

Progression-free survival (BICR)primary
HR 0.45 (0.38–0.54) · p <0.001
Enfortumab vedotin + pembrolizumab
12.5 mo
Platinum + gemcitabine
6.3 mo
Source
Overall survivalprimary
HR 0.47 (0.38–0.58) · p <0.001
Enfortumab vedotin + pembrolizumab
31.5 mo
Platinum + gemcitabine
16.1 mo
Source
Objective response rate
Enfortumab vedotin + pembrolizumab67.7 of 100
Platinum + gemcitabine44.4 of 100
Source
EndpointArmnValueHR (95% CI)pSource
Progression-free survival (BICR)primaryEnfortumab vedotin + pembrolizumab44212.5 months0.45 (0.38–0.54)<0.001link
Platinum + gemcitabine4446.3 months
Overall survivalprimaryEnfortumab vedotin + pembrolizumab31.5 months0.47 (0.38–0.58)<0.001link
Platinum + gemcitabine16.1 months
Objective response rateEnfortumab vedotin + pembrolizumab67.7%link
Platinum + gemcitabine44.4%
Replication
Confirms EV-103 (phase 1b/2, ORR 68%); the extended follow-up in 2025 maintained the OS hazard ratio.

Key papers

1top

Connected

9top

Pages like this

not linked directly; found by shared links